Epizyme Gross Margin 2012-2022 | EPZM

Current and historical gross margin for Epizyme (EPZM) over the last 10 years. The current gross profit margin for Epizyme as of March 31, 2022 is %.
Epizyme Gross Margin Historical Data
Date TTM Revenue TTM Gross Profit Gross Margin
2022-03-31 $0.04B $0.03B 71.79%
2021-12-31 $0.04B $0.03B 71.05%
2021-09-30 $0.03B $0.03B 76.47%
2021-06-30 $0.03B $0.03B 75.76%
2021-03-31 $0.02B $0.02B 68.18%
2020-12-31 $0.02B $0.01B 73.33%
2020-09-30 $0.01B $0.01B 72.73%
2020-06-30 $0.01B $0.01B 92.31%
2020-03-31 $0.02B $0.02B 100.00%
2019-12-31 $0.02B $0.02B 100.00%
2019-09-30 $0.03B $0.03B 100.00%
2019-03-31 $0.03B $0.03B 100.00%
2017-06-30 $0.02B $0.02B 100.00%
2016-12-31 $0.01B $0.01B 100.00%
2016-09-30 $0.01B $0.01B 100.00%
2016-06-30 $0.00B $0.00B 100.00%
2016-03-31 $0.00B $0.00B 100.00%
2015-12-31 $0.00B $0.00B 100.00%
2015-09-30 $0.01B $0.01B 100.00%
2015-06-30 $0.02B $0.02B 100.00%
2015-03-31 $0.03B $0.03B 100.00%
2014-12-31 $0.04B $0.04B 100.00%
2014-09-30 $0.07B $0.07B 100.00%
2014-06-30 $0.07B $0.07B 100.00%
2014-03-31 $0.07B $0.07B 100.00%
2013-12-31 $0.07B $0.07B 100.00%
2013-06-30 $0.04B $0.04B 100.00%
2013-03-31 $0.04B $0.04B 100.00%
Sector Industry Market Cap Revenue
Medical Medical - Biomedical and Genetics $0.075B $0.037B
Epizyme is a development-stage biopharmaceutical company, focused on bringing novel epigenetic therapies for the treatment of cancer and other diseases to the market. The company's proprietary product platform is used to create small molecule inhibitors of a class of enzymes known as histone methyltransferases (HMTs). Epizyme's focus is on inhibiting oncogenic HMTs for the treatment of the underlying causes of associated cancers.
Stock Name Country Market Cap PE Ratio
Bristol Myers Squibb (BMY) United States $162.107B 9.86
Bio-Rad Laboratories (BIO.B) United States $15.121B 32.79
QIAGEN (QGEN) Netherlands $10.761B 16.99
Biohaven Pharmaceutical Holding (BHVN) United States $10.111B 0.00
Ginkgo Bioworks Holdings (DNA) United States $5.648B 0.00
Emergent Biosolutions (EBS) United States $1.770B 7.57
Arcus Biosciences (RCUS) United States $1.376B 34.89
Myovant Sciences (MYOV) United Kingdom $1.033B 0.00
Zymeworks (ZYME) Canada $0.397B 0.00
Gelesis Holdings (GLS) United States $0.345B 0.00
Ambrx Biopharma (AMAM) United States $0.157B 0.00
Enzo Biochem (ENZ) United States $0.110B 22.60
SQZ Biotechnologies (SQZ) United States $0.100B 0.00
ADC Therapeutics SA (ADCT) Switzerland $0.000B 0.00